74157
document
5-Fluorouracil , adriamycin , cyclophosphamide ( FAC ) vs. 5-fluorouracil , epirubicin , cyclophosphamide ( FEC ) in metastatic breast cancer . 94 evaluable patients with metastatic breast cancer were randomly assigned to 5-fluorouracil , adriamycin , and cyclophosphamide ( FAC ) or 5-fluorouracil , epirubicin , and cyclophosphamide ( FEC ) , with cycles repeated every 3 weeks . The objective response rate to FAC was 46 % versus 44 % to FEC . There was no significant difference in the median duration of response and median survival for the two regimens . Toxicity was more frequent and more pronounced in patients receiving FAC . Results indicate therapeutic equivalence of the two regimens and reduced toxicity of the epirubicin arm .
74158
Intervention_Pharmacological
5-Fluorouracil , adriamycin , cyclophosphamide ( FAC )
74159
Intervention_Pharmacological
5-fluorouracil , epirubicin , cyclophosphamide ( FEC )
74160
Intervention_Pharmacological
5-fluorouracil , adriamycin , and cyclophosphamide ( FAC ) or 5-fluorouracil , epirubicin , and cyclophosphamide ( FEC )
74161
Intervention_Pharmacological
FAC
74162
Intervention_Pharmacological
FEC
74163
Intervention_Pharmacological
FAC
74164
Outcome_Physical
objective response rate
74165
Outcome_Physical
median duration of response and
74166
Outcome_Mortality
median survival
74167
Outcome_Adverse-effects
Toxicity
74168
Participant_Condition
metastatic breast cancer
74169
Participant_Condition
94 evaluable patients with metastatic breast cancer